• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN SA Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Switching Antidepressants May Be No Better Than Staying the Course

Switching Antidepressants May Be No Better Than Staying the Course

March 1, 2017
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
The Carlat Report Staff
Review of: Bschor T, Kern H, Henssler J, Baethge C. Switching the antidepressant after nonresponse in adults with major depression: A systemic literature search and meta-analysis. J Clin Psychiatry 2016. doi:10.4088/JCP.16r10749. [Epub ahead of print]

Study type: Meta-analysis

Clinical trials have shown that the response rate of major depression to a course of antidepressants is 50% to 70%. After a non-response, what should we do? Increase the dose? Switch to another medication? Augment with a different one? Unfortunately, we have remarkably little to guide us in the way of empirical studies. The largest “real-world” study of antidepressants, the oft-cited STAR*D trial, enrolled plenty of patients and compared various strategies. Unfortunately, that study was not very informative, because there was no placebo group, and patients were not fully randomized to group assignments.

The authors of this meta-analysis sought evidence to answer a specific question: Is it better to stay the course with the original antidepressant, or is it better to switch? They searched the literature for studies that enrolled patients with major depressive disorder who did not respond to at least a 2-week trial of an antidepressant. These patients were then randomly assigned to either continuation of the same medication or a switch to a different one. They found eight relevant studies, and combining them, 783 patients were randomized to continuation arms while 844 were assigned to switching arms. Some of the studies blinded participants to their treatment, but others did not; the follow-up lasted from 4 to 12 weeks, depending on the study.

The studies spanned a long time period, with the oldest published in 2001 and the most recent in 2014. Medications compared included the following (listed in order of continuation medication, switched-to medication): fluoxetine, mianserin; nortriptyline, fluoxetine; venlafaxine, fluoxetine; escitalopram, duloxetine (two studies); various SSRIs, duloxetine; various SSRIs, mirtazapine; desipramine or citalopram, desipramine or citalopram.

Results
There were no statistically significant differences between patients who continued vs those who switched medications. This was true both for the primary outcome of change in depression scale score and for the secondary outcomes of response rate and remission rate.

TCPR’s Take
This is the largest and best study yet looking at whether it’s better to switch antidepressants or stay the course, and the implication is that there is no advantage to switching.

Practice implications
When patients do not respond to an antidepressant, you may be tempted to switch to another one and then rotate through your list of favorites. But given the surprising finding that switching antidepressants incurs no discernible benefit, you may want to instead consider augmentation strategies or a psychotherapy referral.
General Psychiatry
KEYWORDS depressive_disorder practice-tools-and-tips research-update
www.thecarlatreport.com
Issue Date: March 1, 2017
SUBSCRIBE NOW
Table Of Contents
Pharmacogenetic Testing: An Update
Understanding Pharmacogenetics Research
Switching Antidepressants May Be No Better Than Staying the Course
Take The CME Post-Test for Pharmacogenetics, TCPR, March 2017
DOWNLOAD NOW
Featured Book
  • MFB6eCover.jpg

    Medication Fact Book for Psychiatric Practice, Sixth Edition (2022)

    Guidance, clinical pearls, and bottom-line assessments covering the medications you use in your...
    READ MORE
Featured Video
  • therapist_canstockphoto9201097.jpg
    General Psychiatry

    Using SAMe In Clinical Practice with Garrett Rossi, MD

    Read More
Featured Podcast
  • canstockphoto4921771.jpg
    General Psychiatry

    Psychopharm Commandment #6: MAOIs

    MAOIs rank high in efficacy and are pretty well tolerated too, as long as you watch for two critical interactions.

    Listen now
Recommended
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report

Contact

info@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2023 Carlat Publishing, LLC and Affiliates, All Rights Reserved.